How to Get Tresiba (Insulin Degludec) in Maine

What Is Tresiba and Why Do Maine Patients Request It?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. That extended profile allows once-daily dosing with less peak-to-trough variability than insulin glargine U100. The DEVOTE trial (N=7,637) demonstrated a 40% lower rate of severe hypoglycemia with insulin degludec compared with insulin glargine U100 in high-cardiovascular-risk patients with type 2 diabetes (hazard ratio 0.60; 95% CI 0.48, 0.76; P<0.001) [1]. Maine patients with erratic schedules, frequent nocturnal hypoglycemia, or poor glycemic stability on glargine or detemir are the most common candidates.

The FDA granted approval to insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and later extended approval to pediatric patients aged 1 year and older [2]. Novo Nordisk markets the drug in two concentrations: Tresiba U100 (100 units/mL) and Tresiba U200 (200 units/mL) in FlexTouch pens [2]. The U200 pen is particularly useful for patients requiring more than 40 units per day, since it delivers the full dose in fewer injections. Maine's geography, with large rural stretches and seasonal population shifts, makes that convenience clinically meaningful.

The American Diabetes Association's 2024 Standards of Care note that ultra-long-acting insulins such as insulin degludec and insulin glargine U300 may reduce the risk of nocturnal hypoglycemia compared with insulin glargine U100, though individual responses vary [3]. Endocrinologists at Maine's larger health systems have increasingly adopted degludec as a first-line basal insulin for patients who have experienced even one episode of severe hypoglycemia.

Step 1: Find a Licensed Prescriber in Maine

Any licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) in Maine may prescribe insulin degludec. Maine grants NPs full independent prescribing authority under 32 M.R.S. §2102, meaning NPs do not require a supervising physician agreement to write a Tresiba prescription. PAs in Maine must maintain a written supervision agreement with a physician, though remote co-signature is accepted for telemedicine practice [4].

Telehealth prescribing is fully legal in Maine for new and established patients. Maine follows the federal Ryan Haight Act exemptions that were made permanent after the COVID-19 public health emergency: a prescriber holding a valid Drug Enforcement Administration (DEA) registration may conduct an audio-visual telemedicine visit without a prior in-person examination to prescribe non-controlled medications such as insulin [5]. Insulin is not a controlled substance, so no DEA scheduling restrictions apply.

The HealthRX clinical team uses a three-step intake framework for Maine patients:

1. A structured asynchronous intake questionnaire covering current insulin regimen, HbA1c, hypoglycemia history, and comorbidities.
2. A synchronous 20-minute video visit with a licensed Maine prescriber for medication review and dosing calculation.
3. Same-day or next-day e-prescription sent to the patient's preferred Maine pharmacy.

Patients with an existing endocrinologist or primary care provider in Maine may request a prescription transfer or a referral letter rather than establishing a new prescriber relationship. That route typically adds one to three business days.

Step 2: Required Labs Before Starting Tresiba in Maine

A prescriber will want baseline lab work before initiating insulin degludec, though the specific panel depends on whether the patient is switching from another basal insulin or starting basal therapy for the first time. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends obtaining HbA1c, fasting plasma glucose, a basic metabolic panel (to assess renal function), and a lipid panel at initiation and every three months until glycemic targets are reached [6].

For Maine telehealth patients, labs may be ordered electronically to any Quest Diagnostics, LabCorp, or hospital outpatient lab in the state. Results typically return in 24 to 48 hours. Some prescribers accept recent labs (within 90 days) from a prior provider, which shortens the intake timeline.

Specific thresholds matter. An estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m² warrants extra caution with any insulin, as reduced renal insulin clearance prolongs hypoglycemic risk; the FDA label for insulin degludec does not prohibit use in renal impairment but recommends increased glucose monitoring [2]. Hepatic impairment similarly requires closer monitoring. For patients with HbA1c <7.0% already on basal insulin, a prescriber may opt for dose reduction rather than a direct switch to Tresiba at an equivalent unit count.

Continuous glucose monitoring (CGM) data, if available, can substitute for some fasting glucose measurements and gives the prescriber a clearer picture of nocturnal glucose patterns. The 2024 ADA Standards of Care recommend CGM for all insulin-using adults with diabetes [3].

Step 3: Telehealth Options for Maine Patients

Maine-licensed telehealth platforms that prescribe diabetes medications include national services with Maine prescriber networks as well as regional options tied to Maine Health and Northern Light Health. The key criterion for a patient selecting a platform is whether the provider has a Maine-licensed prescriber available, not simply whether the platform operates in multiple states.

A 2023 analysis published in JAMA Internal Medicine found that telehealth visits for diabetes management were associated with equivalent HbA1c reductions compared with in-person visits at 12 months (mean difference 0.01%; 95% CI -0.12 to 0.14%) [7]. That equivalence supports telehealth as a clinically defensible route for Tresiba initiation in Maine.

Video platforms that comply with HIPAA are required by Maine statute (22 M.R.S. §1711-C). Phone-only visits may be permitted for established patients under certain MaineCare billing codes, but a new Tresiba initiation generally warrants audio-visual contact for physical assessment and injection technique demonstration. Patients should confirm their platform uses TLS-encrypted video before sharing glucose logs or CGM data.

Turnaround from booking to prescription averages 24 to 72 hours on most telehealth platforms with Maine coverage, based on platform-reported data. Urgent consultations for patients with active hypoglycemia or ketosis are routed to emergency services, not telehealth.

Step 4: Filling a Tresiba Prescription at a Maine Pharmacy

Tresiba U100 and U200 FlexTouch pens are stocked at most major chain pharmacies in Maine, including CVS, Walgreens, Hannaford Pharmacy, and Shaw's Pharmacy. Independent community pharmacies in rural Maine (Aroostook County, Washington County) may need 24 to 48 hours to special-order the U200 concentration if not routinely dispensed. Patients are encouraged to call ahead.

The FDA Biosimilar Action Plan and Novo Nordisk's patient assistance program, the NovoCare program, provides Tresiba at no cost or reduced cost to qualifying uninsured or underinsured patients with annual household incomes at or below 400% of the federal poverty level [8]. Maine residents may enroll online or through a prescriber's office. The NovoCare insulin affordability program also caps out-of-pocket costs at $99 per month for commercially insured patients who qualify [8].

For patients with MaineCare, Tresiba is on the preferred drug list subject to prior authorization (see Section 6 below). Commercial insurance coverage varies by plan; step therapy (requiring failure of a less expensive basal insulin such as NPH or glargine biosimilar) is common before degludec is approved.

503A compounding pharmacies in Maine are licensed by the Maine Board of Pharmacy and may compound patient-specific insulin formulations when a commercially available product is not clinically appropriate. For insulin degludec specifically, compounding is uncommon because the commercial product is widely available, but a 503A pharmacy may prepare specific dilutions (for pediatric micro-dosing) upon a valid patient-specific prescription [9]. The FDA's guidance on 503A compounders restricts copying commercially available products without a documented clinical rationale [9].

Step 5: Understanding Prior Authorization for Tresiba in Maine

Prior authorization (PA) is required for Tresiba under MaineCare and most commercial plans in Maine. The documentation packet typically includes five elements: a current HbA1c result, a list of prior basal insulins tried with dates and reason for discontinuation, a diagnosis code (E10.x for type 1 or E11.x for type 2 diabetes), the prescriber's NPI and DEA numbers, and a clinical note explaining medical necessity. Some plans additionally require evidence of at least one hypoglycemic event on a prior basal insulin.

MaineCare's Preferred Drug List, administered by the Maine Department of Health and Human Services (DHHS), classifies Tresiba as a non-preferred agent for type 2 diabetes without prior authorization. The PA criteria for type 2 require documented failure of or contraindication to at least one preferred basal insulin (typically glargine biosimilar or NPH) [10]. For type 1 diabetes, the medical necessity threshold is lower: a diagnosis code and prescriber attestation are often sufficient.

PA approvals in Maine typically take three to five business days through standard review. Expedited review (24 to 72 hours) is available when a prescriber documents that delay would result in serious harm, such as a patient who has been hospitalized for severe hypoglycemia on their current insulin [10]. Telehealth prescribers who submit PA requests on behalf of Maine patients must hold a Maine-issued prescriber license, not merely a telehealth platform registration.

The 2023 American Diabetes Association position statement on insulin access notes that prior authorization processes delay insulin initiation by a mean of 5.7 days and are associated with increased emergency department utilization among low-income patients [11]. "Delays in insulin access due to administrative barriers lead to real clinical harm," states the ADA's 2023 position on insulin affordability [11].

Clinical Evidence Supporting Insulin Degludec

The DEVOTE trial (NCT01959529, N=7,637) remains the definitive cardiovascular outcomes trial for insulin degludec. Published in the New England Journal of Medicine in 2017, DEVOTE showed that insulin degludec was non-inferior to insulin glargine U100 for major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke) in adults with type 2 diabetes at high CV risk (hazard ratio 0.91; 95% CI 0.78, 1.06) [1]. The same trial documented 40% fewer confirmed or severe nocturnal hypoglycemic episodes with degludec (rate ratio 0.63; 95% CI 0.57, 0.70; P<0.001) [1].

The SWITCH 2 trial (N=721), published in The Lancet Diabetes and Endocrinology, used a double-blind crossover design in type 2 diabetes patients and found a 30% lower rate of overall symptomatic hypoglycemia with insulin degludec compared with insulin glargine U100 during the maintenance period (rate ratio 0.70; 95% CI 0.61, 0.80; P<0.0001) [12]. Crossover designs reduce confounding from between-patient differences, making SWITCH 2's hypoglycemia data particularly credible.

For type 1 diabetes, the BEGIN Basal-Bolus Type 1 trial (N=629) showed non-inferior HbA1c reduction with insulin degludec versus glargine (-0.40% vs. -0.39% from baseline) and a 25% lower rate of nocturnal confirmed hypoglycemia (rate ratio 0.75; 95% CI 0.60, 0.94; P=0.011) [13]. That hypoglycemia advantage is the primary reason type 1 patients request Tresiba specifically.

Pediatric data support use in patients aged 1 year and older. A phase 3a trial in children and adolescents (N=350) demonstrated non-inferior HbA1c control and a comparable safety profile to insulin detemir [14]. The FDA extended the pediatric indication in 2019 based on this dataset [2].

The Endocrine Society's 2022 Clinical Practice Guideline on Diabetes Management in Older Adults recommends ultra-long-acting basal insulins for patients aged 65 and older with a history of hypoglycemia, citing insulin degludec specifically as an option with favorable hypoglycemia data [15]. Maine's median age of 45.1 years (the highest of any U.S. state per the 2020 Census) makes that recommendation especially relevant to the state's population.

Transferring an Existing Tresiba Prescription to Maine

Patients relocating to Maine or establishing care after moving can transfer a Tresiba prescription from an out-of-state pharmacy to any Maine-licensed pharmacy. Under Maine pharmacy law (32 M.R.S. §13786), a pharmacist may dispense a transferred prescription for a non-controlled substance if the original prescription was valid and has remaining refills. The original pharmacy faxes or electronically transfers the prescription; no additional prescriber visit is required solely for the transfer.

If the out-of-state prescription has expired or has no refills remaining, the patient must establish care with a Maine-licensed prescriber before a new prescription can be issued. A telehealth visit is the fastest route, averaging 24 to 48 hours from intake to prescription.

Patients on MaineCare who have transferred from another state's Medicaid program should contact Maine DHHS to transfer benefits before their prior authorization lapses. Tresiba PA approvals from other states are not reciprocally recognized; a new PA must be submitted through Maine's process [10].

Dosing Tresiba: What Maine Prescribers Calculate

Insulin degludec is initiated in insulin-naive type 2 diabetes patients at 10 units once daily, or at 0.1, 0.2 units/kg/day, per the FDA prescribing label [2]. Patients switching from another basal insulin start at a unit-for-unit dose conversion from insulin glargine or detemir, with dose adjustments every three to four days based on fasting glucose measurements.

The flexible dosing window of insulin degludec is clinically significant. Because the drug's half-life exceeds 25 hours, the interval between doses may range from 8 to 40 hours without meaningful loss of glycemic control, per a dedicated pharmacokinetic study (N=88) [16]. That flexibility benefits Maine shift workers, fishermen on variable schedules, and agricultural workers during harvest season.

Titration targets align with ADA 2024 Standards: fasting glucose 80 to 130 mg/dL for most adults, with individualized targets for older adults or those with hypoglycemia unawareness [3]. Prescribers typically instruct patients to increase their dose by 2 units every three days if fasting glucose exceeds 130 mg/dL on three consecutive mornings, and to contact the prescriber if a reading falls below 70 mg/dL before breakfast.

Cost and Savings Programs Available to Maine Patients

The list price of Tresiba FlexTouch (5 pens per box) ranges from $380 to $430 per box at Maine retail pharmacies as of early 2025. After Novo Nordisk's voluntary list price reduction of 65% announced in January 2024, the net price for most commercially insured patients dropped substantially, though pharmacy shelf prices may differ from net prices [8].

The Inflation Reduction Act of 2022 caps insulin cost-sharing at $35 per month for Medicare Part D beneficiaries starting January 2023 [17]. Maine Medicare enrollees with Tresiba prescriptions should confirm with their Part D plan that degludec is on the formulary; if not, a formulary exception request citing DEVOTE's hypoglycemia data typically succeeds when documented hypoglycemia exists [17].

State pharmaceutical assistance programs include Maine's Drugs for the Elderly (DEL) program, which helps residents aged 62 and older with medication costs. Tresiba is eligible under DEL for enrollees who meet the income threshold (single person income <$16,862/year as of 2024) [18]. Applications are processed through Maine DHHS.